NeOnc Technologies

Health Cares Blog highlights NeOnc’s home-based treatment option, offering patients greater control over brain cancer management.

A study demonstrates that NeOnc’s NEO100-based intranasal delivery enables brain-targeted treatment with bortezomib, a drug otherwise limited by the blood-brain barrier.

Pharma Tech Outlook discusses NeOnc’s approach to overcoming the blood-brain barrier for glioblastoma treatment.

Meditech Today covers NeOnc’s breakthrough in brain cancer treatment, led by founder and CEO Dr. Thomas Chen.

USA Today profiles NeOnc, Inc., a biotech company led by neurosurgeon Dr. Thomas Chen, which is developing a nasal drug delivery system for brain cancer treatment.

Under 30 CEO features Dr. Thomas Chen’s vision for advancing brain cancer treatment through NeOnc, alongside its executive team.

Venture Beat highlights NeOnc’s executive team and Dr. Thomas Chen’s focus on overcoming challenges in brain cancer research.

NeOnc Technologies Holdings, Inc. focuses on improving drug delivery for brain and CNS diseases to enhance treatment outcomes for patients.

Life Sciences Magazine explains how NeOnc Technologies addresses the blood-brain barrier to improve treatment for brain cancer and CNS disorders.

NeOnc’s NEO100 and NEO212 formulations received Orphan Drug and Fast-Track status for treating high-grade glioma and breast cancer.

NeOnc is a clinical-stage life sciences company developing a novel intranasal drug delivery system and platform technology to treat brain cancers and other central nervous system (CNS) diseases by bypassing the Blood-Brain Barrier (BBB).

NeOnc Technologies appears on *Health Uncensored with Dr. Drew* to present its approach to treating brain tumors. The company highlights a non-invasive method avoiding surgery or systemic chemotherapy. The segment focuses on potential alternatives for patients facing conventional treatment limitations.

Oct 2026GlobeNewswireNews article

NeOnc Technologies and the Department of Health – Abu Dhabi sign a memorandum of understanding (MoU) to advance brain cancer research and explore clinical collaboration. The agreement includes scientific exchange, specialist training, and assessment of clinical trial opportunities, with plans for a potential regional NeOnc presence in Abu Dhabi. Two children in Abu Dhabi are already receiving NeOnc’s investigational therapy **NEO100** through the company’s Compassionate Care program, with a third patient expected shortly.

Oct 2026NeOnc Technologies Holdings, Inc.News article

NeOnc Technologies Holdings reports early clinical improvement in a child treated with its experimental therapy **NEO100** under compassionate use in Abu Dhabi. The patient shows signs of response following administration of the investigational drug, marking the first documented case. NEO100 targets rare pediatric cancers with a novel mechanism, though full efficacy and safety data remain pending.

Oct 2026GlobeNewswireNews article

NeOnc Technologies holds a scheduled FDA meeting on November 17, 2026, to discuss the Phase 2 study design and regulatory pathways for **NEO212**, a therapy targeting central nervous system (CNS) cancers. The company, listed on Nasdaq as **NTHI**, develops clinical-stage biopharmaceutical treatments for brain and CNS malignancies. The meeting follows Phase 1 completion and aims to outline next steps for advancing the drug candidate.

Sep 2026NeOnc Technologies Holdings, Inc.News article